FDA approves first NPC survival treatment - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA approves first NPC survival treatment

  • By

  • Mouj Hijazi

  • November 18, 2026

  • 2 min

Share

  • 1

    The FDA approved adrabetadex (Lembaz) as the first treatment shown to reduce mortality risk in Niemann-Pick disease type C.

  • 2

    Approval covers adults and children weighing at least 7 kg whose neurological symptoms began before age 6.

  • 3

    In a nonrandomized analysis, median overall survival was 102 months with adrabetadex and 59 months in matched external controls, with a 55% lower relative risk of death.

  • 4

    Adrabetadex carries a boxed warning for hearing impairment, including permanent hearing loss, and requires audiological evaluations before treatment and during dose escalation.

  • 5

    Adrabetadex is administered intrathecally every 2 weeks by or under the supervision of a clinician experienced in lumbar punctures.

Original Source(s)

Related Content